Updates on community acquired pneumonia management in the ICU

Pharmacol Ther. 2021 Jan;217:107663. doi: 10.1016/j.pharmthera.2020.107663. Epub 2020 Aug 15.

Abstract

While the world is grappling with the consequences of a global pandemic related to SARS-CoV-2 causing severe pneumonia, available evidence points to bacterial infection with Streptococcus pneumoniae as the most common cause of severe community acquired pneumonia (SCAP). Rapid diagnostics and molecular testing have improved the identification of co-existent pathogens. However, mortality in patients admitted to ICU remains staggeringly high. The American Thoracic Society and Infectious Diseases Society of America have updated CAP guidelines to help streamline disease management. The common theme is use of timely, appropriate and adequate antibiotic coverage to decrease mortality and avoid drug resistance. Novel antibiotics have been studied for CAP and extend the choice of therapy, particularly for those who are intolerant of, or not responding to standard treatment, including those who harbor drug resistant pathogens. In this review, we focus on the risk factors, microbiology, site of care decisions and treatment of patients with SCAP.

Keywords: ATS/IDSA CAP guidelines; CAP severity assessment scores; New antibiotics; Severe community acquired pneumonia; Site of care.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / microbiology*
  • Community-Acquired Infections / mortality
  • Disease Management*
  • Drug Resistance, Multiple, Bacterial
  • Guidelines as Topic
  • Humans
  • Intensive Care Units*
  • Pneumonia / drug therapy*
  • Pneumonia / microbiology*
  • Pneumonia / mortality